Equities

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)11.28
  • Today's Change-0.02 / -0.18%
  • Shares traded250.32k
  • 1 Year change-10.62%
  • Beta0.5944
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Sep 30 2023202320222021
ASSETS
Cash And Short Term Investments370249244
Total Receivables, Net404961
Total Inventory------
Prepaid expenses131314
Other current assets, total------
Total current assets423312319
Property, plant & equipment, net353011
Goodwill, net------
Intangibles, net------
Long term investments029108
Note receivable - long term------
Other long term assets0.800.700.09
Total assets462375439
LIABILITIES
Accounts payable4.106.009.54
Accrued expenses242427
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total35----
Total current liabilities633036
Total long term debt1.421.421.51
Total debt1.421.421.51
Deferred income tax------
Minority interest------
Other liabilities, total181231.68
Total liabilities2465439
SHAREHOLDERS EQUITY
Common stock0.210.210.20
Additional paid-in capital425398351
Retained earnings (accumulated deficit)(207)(73)49
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(1.17)(3.72)(0.38)
Total equity217321399
Total liabilities & shareholders' equity462375439
Total common shares outstanding212120
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.